1. Home
  2. OMCL vs AGIO Comparison

OMCL vs AGIO Comparison

Compare OMCL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omnicell Inc. ($0.001 par value)

OMCL

Omnicell Inc. ($0.001 par value)

HOLD

Current Price

$35.07

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.17

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMCL
AGIO
Founded
1992
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
OMCL
AGIO
Price
$35.07
$29.17
Analyst Decision
Buy
Buy
Analyst Count
7
8
Target Price
$51.14
$37.63
AVG Volume (30 Days)
528.7K
656.0K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$787,309,000.00
$43,011,000.00
Revenue This Year
$6.77
$75.68
Revenue Next Year
$5.22
$167.63
P/E Ratio
$876.50
N/A
Revenue Growth
9.93
N/A
52 Week Low
$22.66
$22.24
52 Week High
$51.84
$46.00

Technical Indicators

Market Signals
Indicator
OMCL
AGIO
Relative Strength Index (RSI) 32.66 55.61
Support Level $33.25 $26.48
Resistance Level $37.51 $29.49
Average True Range (ATR) 1.44 1.11
MACD -0.48 -0.02
Stochastic Oscillator 14.03 63.60

Price Performance

Historical Comparison
OMCL
AGIO

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: